• Successful application would allow for cannabis production and export to EU market
• Emblem Germany cannabis distribution center to be completed later this month
• Experienced senior management team has led the buildout and operation of multiple EU-GMP certified facilities
• Cannabis production operations underway at Paris Facility expansion, three business days following granting of new licence

TORONTO, May 07, 2020 (GLOBE NEWSWIRE) — Aleafia Health Inc.’s (TSX: ALEF, OTC: ALEAF) (“Aleafia Health” or the “Company”) indirect subsidiary, Emblem Germany GmbH (“Emblem Germany”), has formally submitted its application to German regulators for EU Good Manufacturing Practices (“EU-GMP”) certification.

The Company’s newly licensed Paris Facility has been purpose built to meet EU-GMP certification requirements, pharmaceutical-grade production’s highest standard, and as a result, provides wide access to global markets. The application, if successful, would allow the Company’s Paris Facility to produce and export EU-GMP certified cannabis products to the European Union.

Cannabis production operations commenced on May 6, 2020 at the Paris Facility Phase II expansion, only three business days following receipt of the amended Health Canada licence.

Aleafia Health indirectly owns 60 percent of Emblem Germany, by way of a joint-venture between Emblem and German pharmaceutical wholesaler and logistics company, Acnos Pharma GmbH (“Acnos”). It is difficult to ascertain the timeline for securing certification, but the Company intends to continue preparing for an eventual facility inspection.

Aleafia Health and Acnos’ senior management are directing the effort and have previously led the build-out, certification and operation of multiple EU-GMP certified pharmaceutical production facilities in The Netherlands, Germany and North America.

Later this month, Acnos is expected to complete a new state-of-the-art pharmaceutical production and supply chain facility in Aachen Brand, Germany. It contains a dedicated cannabis distribution hub that Acnos owns and Emblem Germany will operate, allowing the Company to commence sales upon receipt of necessary German export and import permits.

“The state-of-art expansion of the Paris Facility, purpose built to meet EU-GMP standards, creates a unique competitive advantage with significant barriers to entry,” said Aleafia Health CEO Geoffrey Benic. “We look forward to leveraging the skillsets of our strong partner Acnos Pharma along with our management team’s in-house EU-GMP expertise.”

“The near completion of our international cannabis distribution center along with Emblem’s Paris Facility Phase II expansion licence are breakthrough milestones toward our goal to achieve a EU-GMP Licence and receiving Emblem-produced cannabis oil products in Germany,” said Maximillian Claudel, Acnos Co-Owner and Managing Director, Emblem Germany.

For Investor & Media Relations:

Nicholas Bergamini, VP Investor Relations
1-833-TSX-ALEF (879-2533)
[email protected]
LEARN MORE: www.AleafiaHealth.com

About Aleafia Health:

Aleafia Health is a vertically integrated and federally licensed Canadian cannabis company offering cannabis health and wellness services and products in Canada and in international markets. The Company operates medical clinics, education centres and production facilities for the production and sale of cannabis.

Aleafia Health owns three significant licensed cannabis production facilities, including the first large-scale, legal outdoor cultivation facility in Canadian history. The Company produces a diverse portfolio of commercially proven, high-margin derivative products including oils, capsules and sprays. Aleafia Health operates the largest national network of medical cannabis clinics and education centres staffed by MDs, nurse practitioners and educators and operates internationally in three continents.

Innovation, the heart of Aleafia Health’s competitive advantage, has led to the Company maintaining a medical cannabis dataset with over 10 million data points to inform proprietary illness-specific product development and its highly differentiated education platform FoliEdge Academy. The Company is committed to creating sustainable shareholder value; the TSX Venture Exchange named Aleafia the 2019 top performing company prior to its graduation to the TSX.

Forward Looking Information

This news release contains forward-looking information within the meaning of applicable Canadian and United States securities laws. Often, but not always, forward-looking information can be identified by the use of words such as “plans”, “expects” or “does not expect”, “is expected”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes” or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Forward-looking information involves known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company or its subsidiaries to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained in this news release. Risks, uncertainties and other factors involved with forward-looking information could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking information, including risks contained in the Company’s annual information form filed with Canadian securities regulators available on the Company’s SEDAR profile at www.sedar.com. Although the Company believes that the assumptions and factors used in preparing the forward-looking information in this news release are reasonable, undue reliance should not be placed on such information and no assurance can be given that such events will occur in the disclosed time frames or at all. The forward-looking information included in this news release are made as of the date of this news release and the Company does not undertake any obligation to publicly update such forward-looking information to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.